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Abstract 
Background :To assess monocyte lymphocyte ratio 
(M/L ratio) as a biomarker to see the outcome of 
therapy and progress of tuberculosis. 
Methods: In this descriptive study 45 newly 
diagnosed cases of tuberculosis and  45 age and sex 
matched healthy controls, were enrolled. The study 
was designed to determine the baseline, initiation 
phase and 2-months maintenance phase treatment 
values of M/L ratio in newly diagnosed active TB 
cases. Blood complete counts were performed  in 
automated haematology analyzer. Manual 
differential leukocyte count was done by microscopy 
to determine M/L ratio.  
Results: The pre-treatment lymphocyte and 
monocyte count in the study group were 
significantly different from the control group, while 
M/L ratio was similar in both the groups. The mean 
M/L ratio in cases and controls were 0.24 ± 0.14 and 
0.24 ± 0.07 respectively. The M/L ratio significantly 
decreased after initiation phase and two months of 
maintenance phase of treatment from baseline 0.24 ± 
0.14 to 0.20 ± 0.10 to 0.19 ± 0.10 with p value of 0.006. 
Conclusions: Tuberculosis is associated with 
increased M/L ratio, which declines and returns to 
normal with antituberculous therapy.  
Key Words: Monocyte Lymphocyte Ratio, 
Antituberculous Therapy 
 
Introduction 
            Tuberculosis is a major health problem and is 
the second leading cause of death by infectious 
diseases after human immunodeficiency virus (HIV). It 
is much more common in low socioeconomic 
communities. Contrary to a global decline in active TB 
cases, Pakistan is still showing a rise despite adopting 
the directly observed treatment short course (DOTS) 
strategy on mass scale. According to WHO statistics, 
Pakistan is placed at 5th number in international 
ranking of tuberculosis with incidence rate of 175 per 
100, 000 population and shares almost half of the 
burden of the disease in East Mediterranean region 
covering 23 countries. 1-3 
     Immune cells, both monocytes and lymphocytes 
have well defined role in innate as well as acquired 
immunity. Tuberculosis is considered to be one of the 
most imperative cause of monocytosis which then 
settles as the infection resolve.4 The results with 
lymphocyte count are still controversial, increasing in 
some cases while decreasing in others and returning to 
normal with therapy.4-6 In addition, with 
lymphocytosis IFN-γ levels are increased at the time of 
diagnosis  which returns to normal with treatment. 
Lymphopenia is also another important marker of 
severe malnutrition along with blood albumin levels 
seen in malnourished individuals.7 Monocytes are the 
target cells for mycobacterial proliferation whereas 
lymphocytes provide resistance to the spread of 
infection causing mycobacterial clearance so it is 
reasonable to suggest that M/L ratio can also be used 
as a prognostic tool in TB. 
      M/L ratio has already been used as a prognostic 
marker in various malignances including colon cancer, 
non-Hodgkin lymphoma and multiple myeloma.8 In 
TB, C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) has been commonly used for 
monitoring the treatment but later, Pakistan chest 
society guidelines revealed that ESR does not have any 
prognostic value.9 In  tuberculous pleural effusion, 
neutrophilia is generally seen in its acute phase.10,11  
 
Patients  and methods 
    This cohort prospective study was conducted 
involving tuberculous patients and controls. Forty five 
newly diagnosed tuberculosis patients from Military 
hospital, Rawalpindi were enrolled via convenient non 
probability sampling and forty five age and sex 
matched healthy controls were taken from the 
community. Tuberculosis was diagnosed on either 
clinical evidence with chest X-ray or Gene Xpert 
studies or sputum smear and culture. Newly 
diagnosed cases with normal body mass index (BMI), 
and age between 18 to 65 years , were inlcuded. 
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Individuals with diabetes mellitus, hypertension, 
obesity and chronic infections were excluded. Blood 
counts were performed on automated haematology 
analyzer .Differential leucocyte count was done by 
making a thin film of blood on a glass slide, followed 
by fixing and staining the cells by Leishman’s stain. A 
total of 100 cells were visualized and out of which 
monocytes and lymphocytes were identified and 
calculated as percentages. M/L ratio was obtained by 
dividing monocyte count in percentage with 
lymphocyte count in percentage.The blood samples 
analysis was done thrice in tuberculous group, i.e. at 
the start of therapy and at the completion of initiation 
phase and end of 4th month of treatment (Table 1). 
Independent T-test and repeated measures analysis of 
variance (ANOVA) were done for statistical analysis 
between the groups. P value < 0.05 was considered 
significant.  
 
Table 1: Experimental design 
 
Group 
Controls 
(H)(n=45) 
Study group (TB cases )(n=45) 
TB 0 TB 2 TB 4 
Group 
description 
Healthy TB cases 
at start of 
treatment 
TB cases at 
end of 2nd  
month of 
treatment 
TB cases at 
end of 4th  
month of 
treatment 
Results 
       Forty five tuberculous patients with mean age of 
38.42 ± 16.11 and BMI 19.95 ± 2.90 were compared 
with forty five healthy controls with mean age 38.27 ± 
15.83 years and BMI 20.76 ± 3.21. Majority (75.6%) 
patients were diagnosed on clinical evaluation and 
chest radiography, whereas 20% patients were 
diagnosed on gene Xpert studies.Only 4.4 % were 
smear positive. Samples were taken at the start of 
therapy (0 month), completion of initiation phase (at 
the end of 2nd month) and during maintenance phase 
(at the end of 4th month). In control group, sampling 
was done at 0 month (start of study). The mean 
monocyte counts in study group were 4.80 ± 2.35, 5.00 
± 2.24 and 5.97 ± 2.43 at the start, end of initiation 
phase and during maintenance phase respectively. In 
control the monocyte count was 7.20 ± 1.76. The mean 
lymphocyte counts at the commencement and 
completion of initiation phase and end of 4th month of 
treatment were 22.07 ± 7.97, 28.20 ± 8.93 and 32.57 ± 
7.36 respectively whereas it was 30.58 ± 8.08 in the 
control group.  M/L ratio in TB0, TB2 and TB4 group 
were 0.24 ± 0.14, 0.20 ± 0.10 and 0.19 ± 0.10 
respectively. In controls it was 0.24 ± 0.07 (Table 
2;Figure 1). Lymphopenia was seen in 23 out 45 cases 
while others showed normal lymphocyte count in 
study group at start of study (Table 3). Comparison of 
monocytes, lymphocytes and Monocyte Lymphocyte 
ratio (M/L) in controls and TB group at 0 month by  
 
Table 2: Monocytes, lymphocytes and M/L ratio 
in controls  and study (tuberculous) group 
  Control 
(0month) 
Study (TB) group  
0month 
(TB0) 
2ndmonth 
(TB2) 
4thmonth 
(TB4) 
Monocytes 7.20  ± 
1.7 
4.80 ± 2.35 5.00 ± 2.24 5.97 ± 2.43 
Lymphocytes 30.58 ±8.0 22.07 ± 
7.97 
28.20 ± 
8.93 
32.57 ± 
7.36 
M/L ratio 0.24 ±0.07 0.24 ± 0.14 0.20 ± 0.10 0.19  ± 0.10 
 
Table 3: Lymphocyte count in study group at the 
time of diagnosis 
 Lymphocyte Count 
Lymphopenia Normal 
lymphocyte 
count 
Lymphocytosis 
n 23 22 0 
 
Table 4: Monocytes, lymphocytes and M/L ratio  in 
controls and study group at 0 month 
 
 
Controls  TB0 Significance 
(p value) 
Mean Mean 
Monocytes 7.20 ± 1.76 4.80 ± 
2.35 
0.00* 
Lymphocytes 30.58 ± 8.08 22.07 ± 
7.97 
0.00* 
M/L ratio 0.249± 0.07 0.24 ± 
0.14 
0.29 
*p value <0.05 is significant 
 
 
Figure 1: Box plot showing M/L ratio in control group,study 
group at 0month, end of 2nd month and end of 4th 
month of treatment showing a significant decline 
 
Mann-Whitney U test revealed  significant difference 
in monocyte and lymphocyte count between controls 
and TB0. However, M/L ratio was same in both the 
groups (Table 4). There was significant difference in 
lymphocyte count and monocyte lymphocyte ratio 
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between TB 0, TB2 and TB4 by Repeated Measures 
Analysis of Variance (Table 5). There was no 
significant difference in lymphocyte neutrophil (L/N) 
ratio in tuberculous patients with and without pleural 
effusion.Study group (TB0) with pleural effusion 
(n=15) had L/N ratio 0.34 ± 0.13 and without pleural 
effusion (n=30) have L/N ratio 0.38 ± 0.17 showing 
that there was no significant difference between these 
two groups(Table 6). 
        
Table 5: Comparison of monocytes, lymphocytes and 
Monocyte Lymphocyte ratio  in study group at 0, end 
of 2 months and end of 4 months 
 
 
TB0 TB2 TB4 Significance 
(p-value) 
Mean Mean Mean  
Monocytes 4.80 ± 
2.35 
5.00 ± 
2.24 
5.97 ± 
2.43 
0.000* 
Lymphocytes 22.07 ± 
7.97 
28.20 ± 
8.93 
32.57 ± 
7.36 
0.000* 
M/L ratio 0.24 ± 
0.14 
0.20 ± 
0.10 
0.19  ± 
0.10 
0.006* 
*p value is <0.05 
 
Table 6: Lymphocyte neutrophil (L/N) ratio in 
tuberculous patients (TB0)  with and without pleural 
effusion 
 Pleural 
Effusion(+) 
No Pleural Effusion 
(-) p value 
n 15 30 
0.492 L/N ratio 
0.34 ± 0.13 0.32 ± 0.17 
    *p value <0.05 is significant. 
 
Discussion  
     The treatment of tuberculosis is long term and 
demands continuous monitoring and motivation on 
part of both patient and doctor. The prognostic 
markers commonly available to monitor the progress 
of disease include CRP, ESR while several other 
expensive and time consuming markers are 
Interleukin (IL) -10, IL-13, and other immune markers 
but a single specific marker for monitoring of 
tuberculosis is yet to be found.12 In present study M/L 
ratio  was calculated in TB patients at commencement 
and completion of initiation phase of antituberculous 
treatment and after 4 months of ATT to identify its role 
in monitoring the effectiveness of treatment.  
     The specificity of chest X-ray in diagnosing TB is up 
to 67%. Sputum smear and culture is the gold standard 
but may give inconclusive results and is time 
consuming. Negative sputum smears do not exclude 
the diagnosis of tuberculosis. Gene Xpert studies is a 
newly introduced, expensive investigation and is less 
readily available for public sector.13,14 Monocytosis is 
commonly seen in tuberculosis. The microorganism 
after entering the body is engulfed by alveolar 
macrophages.  Some microorganisms escape the 
defense mechanisms and succeed to endure, resulting 
in infection with production of chemoattractant 
substances which then invites other leukocytes and 
results in unopposed production of monocytes.14,15  
Malnutrition leads to inappropriate lymphokines 
production which may then lead to altered monocyte 
production and differentiation. This altered 
immunological response might be the reason of 
monocytopenia in present  study. This was supported 
by history of weight loss in TB group which found in 
73 % cases coinciding with the findings of Morris et 
al.15-18  
     Lymphopenia was seen in 50% of our patients at the 
time of diagnosis which later improved with 
treatment. None of the patient showed lymphocytosis. 
Lymphopenia is considered to be due to accumulation 
of lymphocytes at the site of infection leading to 
decreased number in peripheral blood 19. There are 
different studies available mentioning lymphocyte 
count in TB and the effect of TB on lymphocyte count 
is still uncertain. Santiago and colleagues supported 
lymphocytosis while Okamura et al proved 
lymphopenia7 in their study.7,20 
     Shijubo et al published a study in 1992 showing 
decreased CD8 count21. Similarly Astekar et al found 
significantly lower CD4 count with decreased 
CD4/CD8 ratio in reactive cases of TB but CD8 
lymphocytosis in unreactive TB.22 M. tuberculosis 
induces release of various cytokines including 
interferon and multiple interleukins that may 
influence the production of lymphocytes 
predominantly T cells.23. 
    M/L ratio increases with chronic inflammations 
including TB which then settles under the effect of 
antituberculous therapy. A progressive decrease in 
M/L ratio was observed in our study. This is 
supported by a research conducted by Stotz et al on 
colon cancer patients who showed that cases having 
lymphocyte monocyte ratio > 2.38 do not respond to 
chemotherapy. Another recent study by Naranbhai et 
al on 3 to 4 months old children suspecting TB showed 
that M/L ratio has a predictive role in TB, thus helps 
in early detection and prompt treatment of the 
disease.24 
  In this study about one third patients presented with 
pleural effusion which in most cases was exudative 
lymphocytic which is characteristic of tuberculous 
effusion, supporting the findings of previous studies.25 
Infrequently, pleural fluid has  predominance of 
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polymorphs for less than two weeks followed by 
lymphocytic preeminence. 26 L/N ratio is an expedient 
marker of inflammation for foreseeing bacterial 
infection. Patients with earlier tuberculous pleuritis 
show elevated neutrophil count in their pleural fluids 
with elevated adenosine deaminase (ADA) levels. 
Kashinkunti and his co-workers showed a significant 
increase in L/N ratio in patients who developed 
pleural effusion due to tuberculosis.10 
 
Conclusion 
1. M/L ratio can be considered as an independent 
prognostic marker and predictor of anti 
tuberculous treatment.  
2.  Tuberculosis , a disease showing a rising trend in 
our set up, requires to have markers which can be 
helpful in diagnosis and predicting disease course  
 
References 
1. Naseer M, Khawaja A, Pethani AS, Aleem S. How well can 
physicians manage Tuberculosis? A Public-Private sector 
comparison from Karachi, Pakistan. BMC health services 
research. 2013;13(1):439-42. 
2. Khan JA, Malik A. Tuberculosis in Pakistan: are we losing the 
battle? JPMA The Journal of the Pakistan Medical 
Association. 2003;53(8):320-22. 
3. Organization WH. Global tuberculosis report 2013: World 
Health Organization; 2013. 
4. Veenstra H, Baumann R, Carroll NM, Lukey PT. Changes in 
leucocyte and lymphocyte subsets during tuberculosis 
treatment; prominence of CD3dimCD56+ natural killer T 
cells in fast treatment responders. Clinical and experimental 
immunology. 2006;145(2):252-60. 
5. Al-Aska A, Al-Anazi A, Al-Subaei S, Al-Hedaithy M. CD4+ T-
lymphopenia in HIV negative tuberculous patients at King 
Khalid University Hospital in Riyadh, Saudi Arabia. European 
journal of medical research. 2011;16(6):285-87. 
6. Condos R, Rom WN, Liu YM, Schluger NW. Local immune 
responses correlate with presentation and outcome in 
tuberculosis. American journal of respiratory and critical 
care medicine. 1998;157(3 Pt 1):729-35. 
7. Okamura K, Nagata N, Wakamatsu K, Yonemoto K. 
Hypoalbuminemia and lymphocytopenia are predictive risk 
factors for in-hospital mortality in patients with tuberculosis. 
Internal medicine. 2013;52(4):439-44. 
8. Stotz M, Pichler M, Absenger G, Szkandera J. The 
preoperative lymphocyte to monocyte ratio predicts clinical 
outcome in patients with stage III colon cancer. British 
Journal of Cancer. 2014;110(2):435-40. 
9. Javaid PA, Ali PW, Akhter PS. National guidelines for 
management of tuberculosis. PCS publication. 2011;3:1125-
28 
10. Kashinkunti M. Use of pleural fluid lymphocyte neutrophil 
ratio in addition to pleural fluid Adenosine Deaminase for 
the diagnosis of tuberculous pleural effusion. Scholars 
Journal of Applied Medical Sciences . 2014;2:498-501. 
11. Rekha VB, Rajaram K, Kripasankar A, Parthasarathy R. 
Efficacy of the 6-month thrice-weekly regimen in the 
treatment of new sputum smear-positive pulmonary 
tuberculosis under clinical trial conditions. National Medical 
Journal of India. 2012;25(4):196-200. 
12. Djoba Siawaya JF, Beyers N, van Helden P. Differential 
cytokine secretion and early treatment response in patients 
with pulmonary tuberculosis. Clinical and experimental 
immunology. 2009;156(1):69-77. 
13. Piccazzo R, Paparo F, Garlaschi G. Diagnostic accuracy of 
chest radiography for the diagnosis of tuberculosis and its 
role in the detection of latent TB infection. The Journal of 
Rheumatology Supplement. 2014;91:32-40. 
14. Siddiqi K, Lambert ML, Walley J. Clinical diagnosis of smear-
negative pulmonary tuberculosis in low-income countries: 
the current evidence. The Lancet infectious diseases. 
2003;3(5):288-96. 
15. Fenton MJ and Vermeulen MW. Immunopathology of 
tuberculosis: roles of macrophages and monocytes. Infection 
and immunity. 1996;64(3):683-90. 
16. Bhaskaram P and Sundaramma MN. Peripheral blood  
17. monocyte function in malnourished subjects with 
pulmonary tuberculosis. European Jjournal of Clinical 
Nutrition. 1990;44(3):245-48. 
18. Morris CD, Bird  AR, Nell H. The Haematological and 
Biochemical Changes in Severe Pulmonary Tuberculosis. 
QJM. 1989;73(3):1151-59. 
19. Cohen R, Muzaffar S, Capellan J, Azar H. The validity of 
classic symptoms and chest radiographic configuration in 
predicting pulmonary tuberculosis. Chest  
1996;109(2):420-23. 
20. Ozaki T, Nakahira S, Tani K, Ogushi F, Yasuoka S. 
Differential cell analysis in bronchoalveolar lavage fluid 
from pulmonary lesions of patients with tuberculosis. Chest 
Journal. 1992;102(1):54-59. 
21. Montes S J, Gambon DF, Pacheco CM. Cellular immune 
response in tuberculosis: analysis of T-lymphocytes and their 
subsets, B-lymphocytes and natural cytotoxic cells in 
different tuberculosis states and body fluids. Revista Clinica 
Espanola. 1996;196(4):223-27. 
22. Shijubo N, Nakanishi F, Hirasawa M, Sigehara K. Phenotypic 
analysis in peripheral blood lymphocytes of patients with 
pulmonary tuberculosis. Tuberculosis 1992;67(9):581- 
85. 
23. Ashtekar MD, Samuel AM, Kadival GV, Sakhalkar V. T 
lymphocytes in pulmonary tuberculosis. The Indian Journal 
of Medical Research. 1993;97:14-17. 
24. Skogmar S, Schön T, Balcha TT, Jemal ZH, Tibesso G. CD4 
Cell Levels during Treatment for Tuberculosis (TB) in 
Ethiopian Adults and Clinical Markers Associated with CD4 
Lymphocytopenia. PLoS ONE. 2013;8(12):8327- 
30. 
25. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K. Ratio of 
monocytes to lymphocytes in peripheral blood identifies 
adults at risk of incident tuberculosis among HIV-infected 
adults initiating antiretroviral therapy. The Journal of 
Infectious Diseases. 2014;209(4):500-09. 
26. Mehta AA, Gupta AS, Ahmed S. Diagnostic utility of 
adenosine deaminase in exudative pleural effusions. Lung   
2014;31(2):142-44. 
27. Lazarus AA, McKay S, Gilbert R. Pleural tuberculosis. 
Disease-a-Month. 2007;53(1):16-21. 
 
